Patents for A61P 35 - Antineoplastic agents (221,099)
04/2001
04/05/2001WO2001011369A8 Cancer treatments and diagnostics utilizing rad51 related molecules and methods
04/05/2001WO2001005397A8 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same
04/05/2001WO2000073450A3 Cytoskeleton-associated proteins
04/05/2001WO2000073334A3 Human sorting nexins
04/05/2001WO2000071573A3 Immunogenic peptides derived from mage and the use thereof
04/05/2001WO2000069455A3 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
04/05/2001WO2000068198A3 Heterosubstituted pyridine derivatives as pde 4 inhibitors
04/05/2001WO2000067788A3 Use of soluble costimulatory molecules to enhance immune responses
04/05/2001WO2000066752A3 Gene construct for prodrug activation encoding a heterologous, glycosylphophati dylinositol-modified carboypeptidase g2 and a cell surface targettng signal peptide
04/05/2001WO2000066103A3 Contraceptive compositions containing cyclic urea and amide derivatives
04/05/2001WO2000065027A3 Human gil-19/ae289 proteins and polynucleotides encoding same
04/05/2001WO2000061617A3 Transiently immortalized cells for use in gene therapy
04/05/2001WO2000060051A8 Arpe-19 as a platform cell line for encapsulated cell-based delivery
04/05/2001WO2000057860A3 Peroxovanadium compounds as antineoplastic agents for the treatment of cancer
04/05/2001WO2000056891A3 Human transmembrane proteins
04/05/2001WO2000052205A3 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE
04/05/2001WO2000051547A3 Inhibitors of prenyl-protein transferase
04/05/2001WO2000044362A3 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
04/05/2001WO2000040228A3 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
04/05/2001WO2000030668A9 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
04/05/2001WO2000029578A9 Cloning and characterization of two m-rna transcription factors
04/05/2001WO2000020450A9 Calcium channel alpha-2/delta gene
04/05/2001WO2000009120A8 New use of taxoid derivatives
04/05/2001US20010000143 Using dimethyl ether and elevated temperature/pressure to dissolve the solid; releasing the pressure to precipitate the fine powder and expand the ether into a gas; drugs; vitamins; carotenoid, especially beta-carotene; foods; cosmetics
04/05/2001DE19947440A1 1-Aziridino-1-hydroxyiminomethyl-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel 1-Aziridino-1-hydroxyiminomethyl derivatives, processes for their preparation and medicaments containing these compounds
04/05/2001DE19947010A1 Das Gen PRV-1 und dessen Verwendung The PRV-1 gene and its use
04/05/2001CA2388055A1 Immunostimulatory nucleic acids
04/05/2001CA2388025A1 Therapy with 2-5a and interferon
04/05/2001CA2388005A1 Low dose ifn-gamma for treatment of disease
04/05/2001CA2387702A1 The prv-1 gene and use thereof
04/05/2001CA2386346A1 Novel polynucleotides and polypeptides encoded thereby
04/05/2001CA2386197A1 Complementarity determining region-grafted antibody against ganglioside gd3 and derivative of antibody against ganglioside gd3
04/05/2001CA2386032A1 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
04/05/2001CA2386029A1 P-glycoproteins from macaca fascicularis and uses thereof
04/05/2001CA2385888A1 Engineering antibodies that bind irreversibly
04/05/2001CA2385884A1 26 human secreted proteins
04/05/2001CA2385883A1 Human carboxypeptidases and polynucleotides encoding the same
04/05/2001CA2385865A1 Triazolopurine derivatives, pharmaceutical compositions containing the derivatives, and adenosine a3 receptor affinitive agents
04/05/2001CA2385252A1 Anti cancer agent and method of treatment of cancer
04/05/2001CA2385169A1 43 human secreted proteins
04/05/2001CA2385001A1 Pharmaceutically active sulfonyl hydrazide derivatives
04/05/2001CA2384997A1 Pharmaceutically active sulfonyl amino acid derivatives
04/05/2001CA2384981A1 P-glycoproteins and uses thereof
04/05/2001CA2384723A1 Vaccine
04/05/2001CA2384713A1 Colon and colon cancer associated polynucleotides and polypeptides
04/05/2001CA2384662A1 41 human secreted proteins
04/05/2001CA2384659A1 37 human secreted proteins
04/05/2001CA2384265A1 Benzodiazepin derivatives, the production and use thereof
04/05/2001CA2382892A1 Substituted benzimidazol derivatives, processes for preparing them and their use as pharmaceutical compositions
04/05/2001CA2382808A1 22196, a novel human aminopeptidase
04/05/2001CA2352194A1 Azepinoindole derivatives, the production and use thereof
04/04/2001EP1088900A1 Polymorphisms in the human CYP3A4, CYP3A7 and hPXR genes and their use in diagnostic and therapeutic applications
04/04/2001EP1088832A1 Highly resistant granular starch
04/04/2001EP1088823A1 Fused pyrrolocarbazoles
04/04/2001EP1088822A1 Pharmaceutically active sulfonyl hydrazide derivatives
04/04/2001EP1088821A1 Pharmaceutically active sulfonamide derivatives
04/04/2001EP1088819A2 6-azauracil derivatives as thyroid receptor ligands
04/04/2001EP1088815A1 Pharmaceutically active sulfonyl amino acid derivatives
04/04/2001EP1088557A1 Immunisation against cancer with mutated p53
04/04/2001EP1088079A2 Nek-related and bub1-related protein kinases
04/04/2001EP1088072A2 Prostate cancer-associated genes
04/04/2001EP1088069A1 Angiostatin-binding protein
04/04/2001EP1088065A2 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
04/04/2001EP1087997A2 Monoclonal antibodies directed against the g3bp protein, and uses
04/04/2001EP1087994A1 INTERACTION OF p27(KIP1) WITH FKBP-12
04/04/2001EP1087981A2 Prenyl transferase inhibitors
04/04/2001EP1087978A1 Use of diazepins for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors
04/04/2001EP1087971A1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
04/04/2001EP1087970A1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
04/04/2001EP1087963A1 Inhibitors of glycogen synthase kinase 3
04/04/2001EP1087960A1 Macrocyclic analogs and methods of their use and preparation
04/04/2001EP1087959A1 Novel benzopyran or thiobenzopyran derivatives
04/04/2001EP1087954A1 Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
04/04/2001EP1087951A1 Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
04/04/2001EP1087946A1 Aryl alkanoylpyridazines
04/04/2001EP1087937A1 Cyclic hydroxamic acids as metalloproteinase inhibitors
04/04/2001EP1087935A1 Anthracene derivatives as anti-cancer agents
04/04/2001EP1087787A1 Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic lhrh peptides
04/04/2001EP1087786A1 Methods and materials for the treatment of prostatic carcinoma
04/04/2001EP1087785A2 Combination of radiotherapy and anti-angiogenic factors
04/04/2001EP1087768A1 Use of 1-(aminoalkyl)-3-quinoxaline-2-one derivatives for the preparation of compounds having an antioxidant action
04/04/2001EP0788515B1 Non-antigenic branched polymer conjugates
04/04/2001EP0778921B1 Pumping device
04/04/2001EP0636127B1 Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
04/04/2001CN1290269A 5'-deoxycytidine derivatives
04/04/2001CN1290265A Thrombin receptor antagonists
04/04/2001CN1290264A Triazine angiogenesis inhibitors
04/04/2001CN1290260A Hydroxamic and carboxylic acid derivatives
04/04/2001CN1290253A Heterocyclic topoisomerase poisons
04/04/2001CN1290250A Sulfonylamino derivatives which inhibit matrix-degrading metallopr teinases
04/04/2001CN1290247A Process and intermediates useful to make antifolates
04/04/2001CN1290171A Composition and method for regulating cell proliferation and cell death
04/04/2001CN1290168A Inhibition of membrane-associated viral replication
04/04/2001CN1290164A Inhibition of RAF kinase using substituted heterocyclic ureas
04/04/2001CN1289602A Chinese medicine for treating cancer by both internal and external applications
04/04/2001CN1289594A Method for treatment of diseases concerned with cytoplasmic factor
04/04/2001CN1064052C Parathormone related protein human source antibody and its preparation method
04/04/2001CN1063966C Camel thorn preparation and preparing method thereof
04/04/2001CN1063964C Chinese medicine capsule for curing gastric cancers
04/03/2001US6211393 Radicals linked to si are si--o--c, si--s--c or si--n--c type bonds and are hydrolyzable in vivo, forming si--oh bonds that are biologically active especially when in contact with living tissue